39 Prevalence of secondary prevention medication use in South America 2 REFERENCES 1. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Compare [Internet]. GBD Compare Data Visualization. 201AD [cited 2021 Jun 9]. Available from: http://www.healthdata.org/gbd/2019 2. Gaedke MA, Soares Dias da Costa J, Fernandes Manenti E, Henn RL, Vieira Paniz VM, Nunes MF, et al. Use of Institute Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Compare [Internet]. GBD Compare Data Visualization. 201AD [ci.1. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Compare [Internet]. GBD Compare Data Visualization. 201AD [cited 2021 Jun 9]. Available from: http://www.healthdata.org/ gbd/2019 3. Berwanger O, Alberto L, Fernando J, Martin V, Lopes RD, Figueiredo L, et al. Special Article Evidence-Based Therapy Prescription in High-Cardiovascular Risk Patients : The REACT Study. Arq Bras Cardiol. 2013;100(3):212–20. 4. Ergatoudes C, Thunström E, Rosengren A, Björck L, Bengtsson Boström K, Falk K, et al. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome. BMC Cardiovasc Disord [Internet]. 2016;16(1):1–8. Available from: http://dx.doi.org/10.1186/s12872-016-0400-6 5. Herdy AH, López-Jiménez F, Terzic CP, Milani M, Stein R, de Carvalho T, et al. South american guidelines for cardiovascular disease prevention and rehabilitation. Arq Bras Cardiol. 2014;103(2):1–31. 6. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries. Curr Probl Cardiol. 2010;35(2):72–115. 7. Perel P, Avezum A, Huffman M, Pais P, Rodgers A, Vedanthan R, et al. Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Glob Heart. 2015;10(2):99–110. 8. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet. 2011;378(9798):1231–43. 9. Naderi SH, Bestwick JP, Wald DS. Adherence to Drugs That Prevent Cardiovascular Disease : Meta-analysis on 376 ,162 Patients. AJM. 2012;125(9):882-887.e1. 10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–40. 11. Maddox TM, Chan PS, Spertus JA, Tang F, Jones P, Ho PM, et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: Insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2014;63(6):539–46. 12. Avezum A, Oliveira GBF, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda JJ, et al. Secondary CV Prevention in South America in a Community Setting: The PURE Study. Glob Heart. 2017;12(4):305–13. 13. Zhao M, Klipstein-grobusch K, Wang X, Reitsma JB, Zhao D, Grobbee DE, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015 : A systematic review and metaanalysis. 2017;(Ci):1–16. 14. Zhao M, Cooney MT, Klipstein-Grobusch K, Vaartjes I, De Bacquer D, De Sutter J, et al. Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. Eur J Prev Cardiol. 2016;23(11):1202–10. 15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. 16. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan — a web and mobile app for systematic reviews. Systematic Reviews; 2016. 17. Paul A. Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez JGC. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2)(:377-81). 18. Li H, Oldenburg B, Chamberlain C, O’Neil A, Xue B, Jolley D, et al. Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: A systematic review. Diabetes Res Clin Pract. 2012;98(2):226–35. 19. RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA: RStudio, Inc.; 2016. 20. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48. 21. Ribeiro D, Silva RP, Barboza DRMM, Lima-Júnior RCP, Ribeiro RA. Clinical correlation between N-terminal pro-b-type natriuretic peptide and angiographic coronary ather- osclerosis. Clinics. 2014;69(6):405–12. 22. Finimundi HC, Caramori PA, Parker JD. Effect of Diuretic Therapy on Exercise Capacity in Patients With Chronic Angina and Preserved Left Ventricular Function. 2007;49(5):275–9. 23. Hueb W, Soares P, Gersh B, César L, Luz P, Puig E, et al. The Medicine , Angioplasty , or Surgery Study ( MASS-II ): A Randomized , Controlled Clinical Trial of Three Therapeutic Strategies for Multivessel Coronary Artery Disease. J Am Coll Cardiol. 2004;43(10).
RkJQdWJsaXNoZXIy MTk4NDMw